NCT07216105 2025-12-17
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
Fate Therapeutics
DualityBio Inc.
Fate Therapeutics
Hoffmann-La Roche
NKGen Biotech, Inc.